243 related articles for article (PubMed ID: 23190497)
21. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
Roulin D; Demartines N; Dormond O
Biochem Soc Trans; 2011 Apr; 39(2):492-4. PubMed ID: 21428926
[TBL] [Abstract][Full Text] [Related]
22. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer.
Barra F; Evangelisti G; Ferro Desideri L; Di Domenico S; Ferraioli D; Vellone VG; De Cian F; Ferrero S
Expert Opin Investig Drugs; 2019 Feb; 28(2):131-142. PubMed ID: 30574817
[TBL] [Abstract][Full Text] [Related]
23. mTOR pathway inhibition in renal cell carcinoma.
Pinto Marín A; Redondo Sánchez A; Espinosa Arranz E; Zamora Auñón P; Castelo Fernández B; González Barón M
Urol Oncol; 2012; 30(4):356-61. PubMed ID: 20207176
[TBL] [Abstract][Full Text] [Related]
24. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
Danesi R; Boni JP; Ravaud A
Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
[TBL] [Abstract][Full Text] [Related]
25. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
Glen H
Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111
[TBL] [Abstract][Full Text] [Related]
26. Second-line therapy for refractory renal-cell carcinoma.
Zustovich F; Lombardi G; Nicoletto O; Pastorelli D
Crit Rev Oncol Hematol; 2012 Jul; 83(1):112-22. PubMed ID: 21944739
[TBL] [Abstract][Full Text] [Related]
27. Recent advances and future directions in the management of metastatic renal cell carcinoma.
Ansari J; Glaholm J; McMenemin R; James ND; Hussain SA
Anticancer Agents Med Chem; 2010 Mar; 10(3):225-35. PubMed ID: 20184547
[TBL] [Abstract][Full Text] [Related]
28. Targeting mTOR in mantle cell lymphoma: current and future directions.
Smith SM
Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
[TBL] [Abstract][Full Text] [Related]
29. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
[TBL] [Abstract][Full Text] [Related]
30. Roles of EGFR, PI3K, AKT, and mTOR in heavy metal-induced cancer.
Carpenter RL; Jiang BH
Curr Cancer Drug Targets; 2013 Mar; 13(3):252-66. PubMed ID: 23297824
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
32. Biomarker targets and novel therapeutics.
Clouser M; Hess LM; Chambers SK
Cancer Treat Res; 2009; 149():85-105. PubMed ID: 19763432
[No Abstract] [Full Text] [Related]
33. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
Sonpavde G; Choueiri TK; Escudier B; Ficarra V; Hutson TE; Mulders PF; Patard JJ; Rini BI; Staehler M; Sternberg CN; Stief CG
Eur Urol; 2012 Feb; 61(2):307-16. PubMed ID: 22055147
[TBL] [Abstract][Full Text] [Related]
34. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
Calvo E; Ravaud A; Bellmunt J
Cancer Treat Rev; 2013 Jun; 39(4):366-74. PubMed ID: 22832091
[TBL] [Abstract][Full Text] [Related]
35. [New drugs for metastatic kidney cancer].
Doehn C
Aktuelle Urol; 2008 Jan; 39(1):41-52. PubMed ID: 18228187
[TBL] [Abstract][Full Text] [Related]
36. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
37. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
38. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
[TBL] [Abstract][Full Text] [Related]
39. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
40. Targeting the mTOR pathway in tumor malignancy.
Cheng H; Walls M; Baxi SM; Yin MJ
Curr Cancer Drug Targets; 2013 Mar; 13(3):267-77. PubMed ID: 23297825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
